Literature DB >> 17435411

Vitamin D deficiency and secondary hyperparathyroidism among patients with chronic kidney disease.

Samina Khan1.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) is associated with morbid complications that lead to high mortality and costs. Vitamin D deficiency and secondary hyperparathyroidism (SHPT) are frequent complications of CKD.
METHODS: We reviewed the current literature regarding the prevalence, diagnosis, complications, and management of vitamin D deficiency and SHPT among patients with CKD.
RESULTS: There is a high prevalence of vitamin D deficiency among adolescents and adults in the United States (age and gender dependent). Patients with CKD or those who are dialysis-dependent are much more likely to have low levels of vitamin D in comparison to those without kidney disease. In order to avoid significant complications including SHPT and musculoskelatal diseases, vitamin D needs to be measured routinely by primary care physicians and nephrologists. In the majority of CKD patients, SHPT is not diagnosed until late, leading to advanced cardiovascular and bone diseases.
CONCLUSIONS: In conclusion, current management of vitamin D deficiency and SHPT is suboptimal. Early diagnosis of vitamin D deficiency and SHPT are integral to optimal management of CKD, and additional research is needed in this area.

Entities:  

Mesh:

Year:  2007        PMID: 17435411     DOI: 10.1097/MAJ.0b013e31803bb129

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  15 in total

1.  Vitamin D status of children receiving chronic dialysis.

Authors:  Basema I Dibas; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2012-06-03       Impact factor: 3.714

2.  Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease.

Authors:  Pankaj Hari; Nandita Gupta; Smriti Hari; Ashima Gulati; Puneet Mahajan; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2010-09-25       Impact factor: 3.714

Review 3.  Secreted klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.

Authors:  Ema J Jamaluddin; Abdul Halim Abdul Gafor; Loo Chee Yean; Rizna Cader; Rozita Mohd; Norella C T Kong; Shamsul Azhar Shah
Journal:  Clin Exp Nephrol       Date:  2013-08-02       Impact factor: 2.801

5.  Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients.

Authors:  Anne C Beaubrun; Ryan D Kilpatrick; Janet K Freburger; Brian D Bradbury; Lily Wang; M Alan Brookhart
Journal:  J Am Soc Nephrol       Date:  2013-06-06       Impact factor: 10.121

Review 6.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421

7.  Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease.

Authors:  Shina Menon; Rudolph P Valentini; Guillermo Hidalgo; Lena Peschansky; Tej K Mattoo
Journal:  Pediatr Nephrol       Date:  2008-06-25       Impact factor: 3.714

Review 8.  Complementary and alternative medicine therapies to promote healthy moods.

Authors:  Kathi J Kemper; Scott Shannon
Journal:  Pediatr Clin North Am       Date:  2007-12       Impact factor: 3.278

9.  Trends and variations in intravenous vitamin D use among hemodialysis patients in the United States.

Authors:  Anne C Beaubrun; M Alan Brookhart; Betsy Sleath; Lily Wang; Abhijit V Kshirsagar
Journal:  Ren Fail       Date:  2012-10-22       Impact factor: 2.606

10.  Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study.

Authors:  Piergiorgio Messa; Mario Cozzolino; Diego Brancaccio; Giuseppe Cannella; Fabio Malberti; Anna Maria Costanzo; Umberto di Luzio Paparatti; Vincenzo Festa; Giuliana Gualberti; Sandro Mazzaferro
Journal:  BMC Nephrol       Date:  2015-02-06       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.